Baş Onur, Tokatlı Mert, Şavklıyıldız Mehmet, Yazarkan Yiğit, Guduk Naciye, Kılınç Can, Karahan Latif, Şahin Taha Koray, Guven Deniz Can, Aksoy Sercan
Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Department of Internal Medicine, Hacettepe University, Ankara, Turkey.
Expert Rev Anticancer Ther. 2025 Apr;25(4):405-409. doi: 10.1080/14737140.2025.2471010. Epub 2025 Feb 25.
The objective of this study is to evaluate the correlation between survival outcomes and the modified cachexia index (mCXI) in patients with metastatic breast cancer who have been treated with cyclin-dependent kinase (CDK) 4/6 inhibitors.
This study was conducted on patients with metastatic breast cancer who received CDK 4/6 inhibitors (either Palbociclib or Ribociclib) between January 2020 and November 2024.
240 patients were included. A total of 236 patients (98.3%) were female. Median age was 57 (IQR: 48-66 years). The median follow-up period from the initiation of CDK 4/6 inhibitors to the last control was 20 months. One hundred eighty-four patients (76.7%) received ribociclib, while 56 (23.3%) received palbociclib. At diagnosis, 179 patients (74.6%) had metastatic disease. Patients are classified as modified cachexia index-low (mCXI-Low) and mCXI-High according to the receiver operating characteristic (ROC) analysis results for overall survival (OS) prediction [AUC: 0,654 p:<0,001 Cut-off value = 93.5]. Following multivariate analysis, both progression-free survival [HR: 1.50 (95% CI 1.07-2.12), = 0.02] and overall survival [HR: 3.22 (95% CI 1.90-5.46), < 0.001] were found to be significantly associated with mCXI.
mCXI is associated with overall survival in metastatic breast cancer patients who are treated with CDK 4-6 inhibitors.
本研究的目的是评估接受细胞周期蛋白依赖性激酶（CDK）4/6抑制剂治疗的转移性乳腺癌患者的生存结果与改良恶病质指数（mCXI）之间的相关性。
本研究针对2020年1月至2024年11月期间接受CDK 4/6抑制剂（帕博西尼或瑞博西尼）治疗的转移性乳腺癌患者进行。
纳入240例患者。共有236例患者（98.3%）为女性。中位年龄为57岁（四分位间距：48 - 66岁）。从开始使用CDK 4/6抑制剂到最后一次随访的中位随访期为20个月。184例患者（76.7%）接受了瑞博西尼，而56例（23.3%）接受了帕博西尼。诊断时，179例患者（74.6%）已有转移性疾病。根据总生存（OS）预测的受试者工作特征（ROC）分析结果，患者被分为改良恶病质指数低（mCXI-Low）和mCXI高组 [曲线下面积（AUC）：0.654，p < 0.001，临界值 = 93.5]。多因素分析后发现，无进展生存 [风险比（HR）：1.50（95%置信区间1.07 - 2.12），p = 0.02] 和总生存 [HR：3.22（95%置信区间1.90 - 5.46），p < 0.001] 均与mCXI显著相关。
mCXI与接受CDK 4 - 6抑制剂治疗的转移性乳腺癌患者的总生存相关。
